How Monoclonal Antibodies Can Treat COVID-19 and What the Data Says About Vaccines

Monoclonal antibodies from Regeneron (NASDAQ: REGN) and Eli Lilly (NYSE: LLY) designed to bind to the novel coronavirus have delivered solid clinical trial data suggesting they can help patients with COVID-19. In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Brian Orelli discuss the difference between monoclonal and polyclonal antibodies. They also talk about how positive data for the monoclonal antibodies could be good news for companies developing coronavirus vaccines.

Continue reading

Source Fool.com